Navigation Links
Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership

NEWARK, N.J., Jan. 6, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced it has received correspondence from KHA Solutions Group following a December 2010 meeting in Kentucky.

KHA Solutions Group, a for-profit entity and a wholly owned subsidiary of Kentucky Hospital Association, indicated that pending further investigation into BioNeutral and its products, BioNeutral may be selected as a partner in KHA Solutions Group's Affinity Partner Program. KHA Solutions Group exists primarily to support KHA financially, by generating non-dues revenue and is governed by a board of KHA member hospital executives. At board direction, the Affinity Partner Program seeks best-in-class companies which provide a valuable product or service to member hospitals, and forms strategic partnerships with those companies for mutual benefit.  

Referring to the value of a potential partnership as "multi-faceted", KHA Solutions group outlined the additional due diligence that will be necessary before a partnership may be entered, including Ygiene's regulatory approval, negotiation of acceptable financial terms and board approval. Upon acceptance into the program, a marketing plan would be collaboratively developed.

"We are encouraged by our ongoing interactions with KHA Solutions Group," said Dr. Andy Kielbania, PhD, Chief Scientist and Director at BioNeutral, "and are looking forward to partnering with local Kentucky organizations to provide the platform for a new level of safety and effectiveness for hospitals and patients throughout the state."

For more information on BioNeutral, including a listing of company products, leadership and background please visit  

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace.  BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit  

Find us on Facebook:

Follow us on Twitter:

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kentucky Ale Will Be the Official Beer of the Alltech FEI World Equestrian Games
2. Dr. Fred Ueland, Markey Cancer Center, University of Kentucky Presents OVA1™ High Sensitivity Data at the 13th Annual International Gynecologic Cancer Society Meeting
3. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
4. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
5. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
6. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
7. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
8. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
9. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
10. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
11. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
Post Your Comments:
(Date:11/30/2015)... San Jose, CA (PRWEB) , ... ... ... the Content Intelligence Company, today announced tighter software integration with MarkLogic, the ... management where organizations maximize information to drive change. , Smartlogic’s Content Intelligence ...
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
Breaking Biology News(10 mins):